Publicacións (31) Publicacións de Francisco José Maceiras Pan

filter_list

2026

  1. Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis

    PLOS ONE, Vol. 21, Núm. 3 March

2025

  1. Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry

    Rheumatology, Vol. 64, Núm. 6, pp. 3733-3738

  2. Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study

    ARTHRITIS & RHEUMATOLOGY

  3. Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: Insights from the ARTESER registry

    Rheumatology, Vol. 64, Núm. 9, pp. 4985-4994

  4. Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry

    Arthritis Research and Therapy, Vol. 27, Núm. 1

  5. Semaphorin4B is elevated in rheumatoid arthritis and enhances the inflammatory phenotype of macrophages and fibroblast-like synoviocytes

    Arthritis Research & Therapy, Vol. 27, Núm. 1

  6. Visual manifestations in giant cell arteritis: Identification of risk factors from the ARTESER Registry

    Rheumatology, Vol. 64, Núm. 2, pp. 697-703

2024

  1. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice

    Reumatologia Clinica, Vol. 20, Núm. 1, pp. 24-31

  2. Semaphorin3B promotes an anti-inflammatory and pro-resolving phenotype in macrophages from rheumatoid arthritis patients in a MerTK-dependent manner

    Frontiers in Immunology, Vol. 14

  3. The activity of psoriatic arthritis with axial involvement correlates with the PsAID12

    Reumatologia Clinica, Vol. 20, Núm. 2, pp. 80-83

2022

  1. Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology

    BMC Health Services Research, Vol. 22, Núm. 1

2021

  1. Direct costs in patients with chronic inflammatory arthropathies on biological therapy: A real-world data study

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 4, pp. 736-745

  2. Epidemiological Characteristics and Adverse Events of Patients with Psoriatic Arthritis Undergoing Treatment with Biological Therapies in Galicia

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 150-154

  3. Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study

    European Journal of Hospital Pharmacy, Vol. 28, Núm. e1, pp. E47-E50

  4. Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice

    Reumatologia Clinica, Vol. 17, Núm. 4, pp. 203-206

2020

  1. Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project

    Reumatologia Clinica, Vol. 16, Núm. 1, pp. 24-31

  2. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332

  3. Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 116-119

2019

  1. Adherence to biological therapies in patients with chronic inflammatory arthropathies

    Farmacia Hospitalaria, Vol. 43, Núm. 4, pp. 134-139

  2. Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab

    Medicine, Vol. 98, Núm. 26, pp. e15947